J B Chemicals & Pharmaceuticals Ltd Q1 FY26 – Torrent Swallows a 49-Year-Old Pill With 25% Margins
1. At a Glance
J B Chemicals, the company behind Rantac, Nicardia, Metrogyl and your chemist’s favorite “sir, yeh generic ka bhi hai?” alternatives, has turned into the hottest acquisition meal on the pharma thali. With Q1 FY26 revenue ₹1,094 Cr (+9% YoY), PAT ₹202 Cr (+14% YoY), and EBITDA margins holding at 28%, this 1976-born company is punching like a mid-weight champion. Stock trades at ₹1,720 (P/E 39x) with ROCE at a juicy 26%. And Torrent Pharma just announced it’ll acquire control at ₹11,917 Cr, throwing in an open offer at ₹1,639.18/share. Spoiler: the market already priced in the drama.
2. Introduction
Once upon a time in Gujarat, J B Chemicals started with lozenges and basic formulations. Fast-forward 49 years and it is a mid-cap pharma darling, balancing between India, Russia, and Africa like a doctor juggling patients on a Monday morning.
The domestic business (55% of revenue) is built on blockbuster brands: Rantac (antacid), Cilacar (hypertension), Metrogyl (amoebicide), and Nicardia (calcium channel blocker). These medicines are so popular that they probably deserve their own Bollywood brand ambassador. Internationally, JBCPL is everywhere from Russia to South Africa to Latin America, making money off distributors and contract manufacturing gigs.
But here’s the masala: in June 2025, Torrent Pharma swooped in with a 46.39% stake buy, valuing J B Chemicals at ~₹25,689 Cr, and immediately announced a merger plan. Translation: JBCPL is no longer an independent entity but a mid-cap with a Torrent-sized umbrella.
The irony? Investors who thought they were holding a simple pharma stock now find themselves unwilling contestants in a M&A drama. Should they cheer Torrent’s big-brother capital infusion or grumble about open-offer prices being lower than CMP?
3. Business Model – WTF Do They Even Do?
Think of JBCPL as a pharma dhaba with four thalis:
Domestic formulations (55%) – The spicy gravies like Rantac, Cilacar, Nicardia, Metrogyl. Basically, top 100 ranked brands keep the plates full.
Export formulations (30%) – Sold through direct presence in Russia and South Africa, plus distributors in the U.S. and 50+ countries. These are like franchise outlets abroad.
Contract Manufacturing (13%) – JBCPL is the behind-the-scenes cook for other big pharma chains.
APIs (2%) – Just a side dish, not the main meal.
They run 8 plants across Gujarat & Daman with 40+ international accreditations. Capex is focused on lozenges expansion (Daman facility – ₹93 Cr spent in H1 FY24).
Question: When was the last time you actually asked for Rantac instead of Gelusil or Digene? That’s the power of chronic category branding.
Commentary: QoQ PAT growth of 38% is healthier than your morning turmeric latte. OPM back at 28%, showing Torrent’s buyout wasn’t of a struggling company but of a money-printing mid-cap.
